Background: As new treatments for head and neck cancer arise, further information is required regarding resource utilization. The Canadian Cancer Trials Group HN.6 study included collected resource utilization data prospectively on patients with locally advanced squamous cell carcinoma of the head and neck treated with cisplatin or panitumumab plus radiotherapy (RT). Methods: The HN.6 phase III trial enrolled 320 patients across Canada between 2008-2011. The economic analysis was conducted from the societal perspective. Resource utilization was collected prospectively for 3 categories: outpatient, hospitalization and institutionalization (end of life care) at baseline, 8 weeks, every 3 months(mo) for 2 years and every 4 mo until 3 years. Lost productivity questionnaires were collected in the last week of RT. Descriptive statistics were used to summarize the outcomes. Categorical variables were reported by percentage and continuous variables were reported by mean and standard deviation. Results: Of 320 pts randomized, resource utilization and lost productivity data were available for 317 (99%) and 285 (89%) pts, respectively. Eighty nine pts required 130 emergency room visits (mean 1.46±0.85). There were 696 (mean 3.74±3.22) office visits among 186 pts and 367 (mean 3.95±6.43) outpatient visits among 93 pts. Surgeons, radiation oncologists and emergency room physicians were the top three providers of outpatient care with 234 (mean 2.05±1.54), 137 (mean 1.67±1.19) and 118 (mean 1.4±0.78) visits for 114, 82 and 84 pts, respectively. CT scans (286), lab tests (418), x-rays (182) and other tests (400) were conducted in 136, 180, 120 and 194 pts, respectively. Three pts were institutionalized for end of life care (mean 28 days±26.06), and 214 pts were hospitalized (mean 14.5 days±28.8). One hundred and thirteen (41%) pts reported a change in work status at the end of RT. Conclusions: Radical treatment for locally advanced SCCHN is resource intensive. Tracking resources utilized prospectively in clinical trial settings and reporting this information consists of an efficient way to inform health resource allocation decisions. Clinical trial information: NCT00820248